Abstract
Systemic administration of cytokines has not found broad application in cancer immunotherapy due to its toxicity and lack of effectiveness in a broad spectrum of tumors. Among the most promising cytokines used often in pre-clinical and clinical trials are interferon alpha and interleukin 12. We have shown in our study that combining IL-12 with IFN-α in a dose which alone does not show antitumor activity results in potentiated antitumor effects without inducing toxicity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 358-361 |
| Number of pages | 4 |
| Journal | Neoplasma |
| Volume | 48 |
| Issue number | 5 |
| State | Published - 2001 |
| Externally published | Yes |
Keywords
- Interferon alpha
- Interleukin 12
- Melanoma
- Mice
ASJC Scopus subject areas
- Cancer Research
Fingerprint Dive into the research topics of 'Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice'. Together they form a unique fingerprint.
Cite this
Dabrowska, A., Giermasz, A., Golab, J., & Jakóbisiak, M. (2001). Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma, 48(5), 358-361.